Financial results in brief
02 September, 2005 by Staff WritersCancer therapy developer Meditech (ASX:MTR) has received an AusIndustry Commercial Ready Grant worth $2.988 million over the next three years towards the development and commercialisation of HyCAMP, its lead anti-cancer product which is in phase II clinical testing. Meditech has also reported a half year loss of $1.68 million and a cash balance of $3.4 million.
Peplin cancer drug in US dose-escalation trial
01 September, 2005 by Graeme O'NeillBrisbane oncology-drug developer Peplin (ASX:PEP) has begun a phase IIa dose-escalation trial of its PEP005 lead product for pre-cancerous skin lesions, or actinic keratoses (AKs) caused by ultraviolet radiation in sunlight.
Clinical Trials Victoria unveils new name, CEO
30 August, 2005 by Ruth BeranNucleus Network, the new umbrella name for Clinical Trials Victoria (CTV), the Centre for Clinical Studies (CCS) and its member alliances, was launched today at the organisation's facility, located adjacent to Melbourne's Alfred Hospital -- three hours after a 12-patient clinical trial finished in the same room
Amrad maintains strong cash position
29 August, 2005 by Helen SchullerAmrad (ASX:AML) has reported a healthy cash position of AUD$51.7 million and an operating loss of AUD$1.622 million for the year ended 30 June 2005, down from $3.523 million last year.
New movement laboratory launched
26 August, 2005 by Ruth BeranAustin Health's new movement laboratory has been opened at the Royal Talbot Rehabilitation Centre in Kew, Melbourne to provide a clinical movement analysis service to assist people with disabilities to become more independent.
WA team IDs leukaemia key
24 August, 2005 by Graeme O'NeillResearchers at the Western Australian Institute for Medical Research (WAIMR) have identified a key gene in acute myeloid leukaemia (AML) that could serve both as a prognostic marker and a target for new drugs to treat the disease.
Astop Biohealth plans ASX listing
22 August, 2005 by Ruth BeranAstop Biohealth, an unlisted natural medicines company established in 2001 and chaired by Perth entrepreneur Kevin Parry, is planning to list on the ASX before the end of the year.
Amrad and Merck select lead antibody for asthma
17 August, 2005 by Ruth BeranMelbourne-based Amrad (ASX:AML) and research partner Merck & Co have selected a lead therapeutic antibody for full preclinical development as a potential treatment for asthma and other types of respiratory disease.
TGR nets $3m in venture funding
17 August, 2005 by Helen SchullerUnlisted Adelaide-based firm TGR Biosciences has attracted up to AUD$3 million funding from venture capital firm Nanyang Ventures to further clinical development of its treatment for oral mucositis, a debilitating side-effect of cancer treatments.
From Chile via WEHI: new MS drug candidate
17 August, 2005 by Graeme O'NeillResearchers at the Walter and Eliza Hall Medical Research Australian and the University of California have developed one of the hottest prospective drug therapies for the paralysing neurodegenerative disorder multiple sclerosis (MS).
Biotron pioneer dies
16 August, 2005 by Ruth BeranPeter Gage, an internationally recognised pioneer of the use of ion channels as a treatment for viral diseases, died on August 13 after a long illness.
Tysabri news boosts Antisense
11 August, 2005 by Iain ScottReports that a potential blockbuster drug for multiple sclerosis, Tysabri, could be back on shelves later this year appear to have given a boost to Melbourne company Antisense Therapeutics (ASX:ANP), which is also developing an MS drug.
NeuroSearch halts Alzheimer's drug plan
11 August, 2005 by Staff WritersDanish biotech firm NeuroSearch has decided not to start clinical development of drugs aimed at treating Alzheimer's disease.
Cervical cancer vaccine pioneer wins leadership prize
11 August, 2005 by Helen SchullerProf Ian Frazer, whose research on a vaccine for a leading cause of cervical cancer is being developed by CSL and Merck & Co, has won the inaugural 2005 CSIRO Eureka Prize for Leadership in Science.
Peplin bows to pressure, reinstates leukaemia program
03 August, 2005 by Ruth BeranPeplin (ASX:PEP) is set to raise AUD$4 million through the issue of 11.4 million ordinary shares at $0.35 per share to institutional and sophisticated investors.
